Compare IMPP & CABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IMPP | CABA |
|---|---|---|
| Founded | 1981 | 2017 |
| Country | Greece | United States |
| Employees | 49 | N/A |
| Industry | Marine Transportation | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 169.2M | 319.6M |
| IPO Year | N/A | 2019 |
| Metric | IMPP | CABA |
|---|---|---|
| Price | $4.35 | $2.96 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | N/A | ★ $14.57 |
| AVG Volume (30 Days) | 797.5K | ★ 2.2M |
| Earning Date | 03-06-2026 | 03-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $50.34 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $3.68 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.12 | $0.99 |
| 52 Week High | $6.57 | $3.78 |
| Indicator | IMPP | CABA |
|---|---|---|
| Relative Strength Index (RSI) | 52.12 | 46.30 |
| Support Level | $4.28 | $2.11 |
| Resistance Level | $4.84 | $3.34 |
| Average True Range (ATR) | 0.27 | 0.21 |
| MACD | -0.02 | -0.06 |
| Stochastic Oscillator | 46.70 | 17.50 |
Imperial Petroleum Inc is a provider of international seaborne transportation services to oil producers, refineries, and commodities traders. It owns and operates a fleet of six medium-range product tankers that carry refined petroleum products such as gasoline, diesel, fuel oil, and jet fuel, as well as edible oils and chemicals.
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.